Perrigo Company plc Cash and Restricted Cash
Perrigo Company plc (PRGO) had Cash and Restricted Cash of $399.70 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-27: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $399.70M.
- 2026-03-28: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $357.20M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $531.60M.
- 2025-09-27: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $432.10M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-27 | $399.70M 10-Q · filed 2026-08-05 | |
| 2026-03-28 | $357.20M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $531.60M 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $432.10M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $454.20M 10-Q · filed 2026-08-05 | |
| 2025-03-29 | $409.90M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $558.80M 10-Q · filed 2026-08-05 | |
| 2024-09-28 | $1.46B 10-Q · filed 2025-11-05 | |
| 2024-06-29 | $542.80M 10-Q · filed 2025-08-06 | |
| 2024-03-30 | $658.50M 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $751.30M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $598.30M 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $555.20M 10-Q · filed 2024-08-02 | |
| 2023-04-01 | $553.00M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $600.70M 10-K · filed 2026-02-26 | |
| 2022-10-01 | $468.70M 10-Q · filed 2023-11-07 | |
| 2022-07-02 | $485.30M 10-Q · filed 2023-08-08 | |
| 2022-04-02 | $1.97B 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $1.86B 10-K · filed 2025-02-28 | |
| 2021-10-02 | $2.08B 10-Q · filed 2022-11-08 | |
| 2021-07-03 | $317.50M 10-Q · filed 2022-08-09 | |
| 2021-04-03 | $470.90M 10-Q · filed 2022-05-11 | |
| 2020-12-31 | $631.50M 10-K · filed 2024-02-27 | $641.50M 10-K · filed 2021-03-01 |
| 2020-09-26 | $840.20M 10-Q · filed 2021-11-12 | $849.40M 10-Q · filed 2020-11-05 |
| 2020-06-27 | $1.44B 10-Q · filed 2021-08-11 | $1.46B 10-Q · filed 2020-08-05 |
| 2020-03-28 | $491.70M 10-Q · filed 2021-05-12 | $510.40M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $344.50M 10-K · filed 2023-02-28 | $354.30M 10-K · filed 2020-02-27 |
| 2019-09-28 | $398.50M 10-Q · filed 2020-11-05 | |
| 2019-06-29 | $1.06B 10-Q · filed 2020-08-05 | |
| 2019-03-30 | $837.90M 10-Q · filed 2020-05-05 | |
| 2018-12-31 | $541.90M 10-K · filed 2022-03-01 | $551.10M 10-Q · filed 2019-05-09 |
| 2018-09-29 | $444.20M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $526.50M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $687.30M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $678.70M 10-K · filed 2021-03-01 | |
| 2016-12-31 | $622.30M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |